0001193125-19-179939.txt : 20190725 0001193125-19-179939.hdr.sgml : 20190725 20190624150533 ACCESSION NUMBER: 0001193125-19-179939 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 CORRESP 1 filename1.htm CORRESP

June 24, 2019

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention:

Sharon Blume

Justin Dobbie

Andi Carpenter

Julie Griffith

 

Re:

Adaptive Biotechnologies Corporation

Registration Statement on Form S-1

File No. 333-231838

Acceleration Request

Requested Date:              Wednesday, June 26, 2019

Requested Time:             4:00 p.m., Eastern Daylight Time

Ladies and Gentlemen:

Pursuant to Rule 460 under the Securities Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that between June 17, 2019 and June 23, 2019 at 5:00 p.m., Eastern Daylight Time, approximately 3,135 copies of the Preliminary Prospectus of Adaptive Biotechnologies Corporation, a Washington corporation (the “Registrant”), dated June 17, 2019, were distributed to prospective underwriters/dealers, institutional and other investors and others.

We, the undersigned Representatives, have and will, and we have been informed by the participating underwriters that they have and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering.

In accordance with Rule 461 of the Securities Act, we hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Daylight Time on June 26, 2019, or as soon thereafter as practicable. We, the undersigned Representatives, confirm that the underwriters are aware of their obligations under the Securities Act.

[Signature Page Follows]

Very truly yours,
GOLDMAN SACHS & CO. LLC
J.P. MORGAN SECURITIES LLC
BOFA SECURITIES, INC.
As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement
GOLDMAN SACHS & CO. LLC
By:  

/s/ Elizabeth Wood

  Name: Elizabeth Wood
  Title: Managing Director
J.P. MORGAN SECURITIES LLC
By:  

/s/ Benjamin Burdett

  Name: Benjamin Burdett
  Title: Managing Director
BOFA SECURITIES, INC.
By:  

/s/ Adam Chazan

  Name: Adam Chazan
  Title: Managing Director

cc:

Chad Robins, Chief Executive Officer

Chad Cohen, Chief Financial Officer

Stacy Taylor, General Counsel

Adaptive Biotechnologies Corporation

James Evans, Esq.

Robert Freedman, Esq.

Amanda Rose, Esq.

Fenwick & West LLP

Andrew Ledbetter, Esq.

Tyler Hollenbeck, Esq.

Kevin Criddle, Esq.

DLA Piper LLP (US)